Celgene to acquire Juno Therapeutics for approximately $9 billionStaff Writer | January 22, 2018
Celgene Corporation has agreed to acquire Juno Therapeutics. Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene(approximately 9.7% of outstanding shares).
Acquisition Juno is a pioneer in the development of CAR
Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications.
Adding to Celgene's lymphoma program, JCAR017 (lisocabtagene maraleucel; liso-cel) represents a potentially best-in-class CD19-directed CAR T currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).
Regulatory approval for JCAR017 in the U.S. is expected in 2019 with potential global peak sales of approximately $3 billion. ■